Skip to main content

Table 7 Performance of the four-marker model (IGF2+ IL6+ AFP+ platelet count) according to the BCLC, CLIP, and Okuda staging systems

From: A novel model based on interleukin 6 and insulin-like growth factor II for detection of hepatocellular carcinoma associated with hepatitis C virus

Classification AUC (95% Cl) Sens% Spe% PPV% NPV% AC%
Number of nodules (n, %)
 Single (67, 43.2%) 0.95 (0.89-1.0) 90 85 82 92 87
 Multiple (88, 56.8) 0.95 (0.88-1.0) 90 85 82 92 87
Macro vascular invasion (n, %)
 Absent (141, 91%) 0.94 (0.86-1.0) 88 85 88 85 86
 Present (14, 9%) 1.0 (1.0-1.0) 100 85 67 100 88
Size of nodules (n, %)
 < 2 (48, 31%) 0.95 (0.87-1.0) 92 85 85 92 88
 > 2 (107, 69%) 0.98 (0.93-1.0) 94 85 88 92 99
BCLC stage (n, %)
 0-A (109, 70.3%) 0.93 (0.96-1.0) 83 85 83 85 84
 B (46, 29.7) 0.99 (0.96-1.0) 100 85 80 100 91
CLIP stage (n, %)
 0-1 (122, 79%) 0.94 (0.85-1.0) 87 85 87 85 86
 2-3 (33, 21%) 1.0 (1.0-1.0) 100 85 71 100 89
Okuda stage (n, %)
 Stage I (117, 75.5%) 0.95 (0.88-1.0) 92 85 86 92 89
 Stage II (38, 24.5%) 0.96 (0.87-1.0) 86 85 75 92 85